Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “GASTROINTESTINAL DISEASE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 433 records · Page 24Linked to original sources
PubMed1984

Gastric microbial flora in patients with gastrointestinal disease.

We designed a prospective study to test the hypothesis that the stomach may be a bacterial reservoir in some patients and function as a potential source of aspiration-induced bacterial pneumonia. Quantitative cultures of fasting gastric contents were obtained in 100 consecutive patients having fiberoptic endoscopy for evaluation of gastrointestinal disease. Culture results were correlated with gastric pH and gastrointestinal pathology. Patients with gastric ulcer disease had a significantly higher incidence of bacterial growth than those with duodenal ulcer. Patients who had had gastrectomy were more likely than any others to have gram-negative bacilli in their stomach. A somewhat high frequency of other common pneumonic pathogens in gastric contents was also noted. The significance of these findings in the production of pneumonia in the elderly is discussed.

Bacteria↗
PubMed2005

Probiotics and gastrointestinal diseases.

There is increasing evidence indicating health benefits by consumption of foods containing microorganisms, i.e. probiotics. A number of clinical trials have been performed to evaluate the effects in the prevention and treatment of gastrointestinal diseases caused by pathogenic microorganisms or by disturbances in the normal microflora. Gastrointestinal infections caused by Helicobacter pylori, traveller's diarrhoea, rotavirus diarrhoea, antibiotic-associated diarrhoea (AAD) and Clostridium difficile-induced diarrhoea are conditions that have been studied. There are also studies performed on the preventive effect of probiotics on radiation-induced diarrhoea and diarrhoea in tube-fed patients. Inflammatory bowel disease and irritable bowel syndrome, two idiopathic conditions where alterations in the normal microflora have been implicated as responsible for initiation, are two further areas where the use of probiotics has been regarded as promising. The results from clinical studies have not been conclusive in that the effects of probiotics have been strain-dependent and different study designs have been used. Treatment of acute diarrhoea in children and prevention of AAD are the two most justified areas for the application of probiotics.

Acute Disease↗
PubMed1987

Gastrointestinal disease amongst Polish migrants in Nottingham.

The main Polish migrations to Britain were in the 1940s and many families have retained a traditional diet. People of Polish origin living in Nottingham were interviewed and the frequency of gastrointestinal disease assessed. Gallstones were less common in English people and Polish migrants than in Poland. Appendicitis and haemorrhoids were commoner in Polish migrants that amongst people in Poland.

Adolescent↗
PubMed2004

Early cytomegalovirus (CMV) gastrointestinal disease that developed 19 days after bone marrow transplantation, with a high-level of CMV antigenemia, of up to 1120 cells/slide.

We report a 19-year-old male with acute myeloid leukemia who developed an early cytomegalovirus gastrointestinal disease with a high level of cytomegalovirus antigenemia after bone marrow transplantation. He underwent bone marrow transplantation from HLA-matched related donor. He developed acute graft-versus-host disease on day 15, and he immediately went on prednisolone. The graft-versus-host disease disappeared immediately, but he developed a severe epigastralgia on day 23. Although absolute neutrophil count was 0.5 x 10(9)/l, the pp65 cytomegalovirus antigenemia increased up to 1120 cells/slide. The endoscope examination was performed on day 29 and it showed erosive gastritis, and microscopical examination revealed nuclear inclusion bodies and positive cells of cytomegalovirus antigen. Ganciclovir treatment was started, and it continued until negative cytomegalovirus antigenemia was confirmed. He consequently discharged to outpatient without late phase CMV diseases or recurrence of AML. We assessed that the patient had two risk factors. First, he was the cytomegalovirus seropositive patient and received bone marrow from seronegative donor. Second, he was treated with prednisolone for acute graft-versus-host disease. The ganciclovir treatment turned out to be successful, but the cytomegalovirus disease developed too early to start the antigenemia guided preemptive treatment. The high-risk patients could develop the early cytomegalovirus disease even though under the status of myelosuppression after bone marrow transplantation.

Adult↗
PubMed1998

Modelling different approaches to the management of upper gastrointestinal disease.

A treatment algorithm for the management of upper gastrointestinal (UGI) disease in general practice has been developed by an international group of general practitioners [the International Gastro Primary Care Group (IGPCG)]. When the algorithm was evaluated to consider the overall cost per patient, it was shown to offer savings over current practice in the UK. Adjustments to the algorithm have been proposed, usually on the basis of variations in the place and timing of Helicobacter pylori testing and eradication, with or without endoscopy. This paper evaluates the current cost of UGI disease in the UK, the base IGPCG algorithm and the 5 major alternative scenarios. The original IGPCG algorithm was the least costly option of all those considered, with additional H. pylori testing for all patients with suspected ulcer being the second least expensive option. Routine endoscopies for all patients or for all patients aged more than 45 years were the most expensive scenarios and would require a 16- or 13-fold increase, respectively, in the provision of endoscopy services in the UK. The use of routine endoscopy for all patients aged more than 45 years who were presenting with UGI symptoms for the first time was a mid-priced option, but would still require a 5-fold increase in the provision of endoscopy services. The modelling process highlights the fact that early stratification of patients into diagnostic and treatment groups, on the basis of history and symptom cluster, is a less costly approach than that of early routine endoscopy or H. pylori testing. If H. pylori testing is to be used routinely, then the least costly way is to apply the method to those patients who have symptoms that are more indicative of ulcer disease. All the scenarios considered resulted in lower drug costs than current average UK drug costs per patient per year, and in fewer prescriptions and general practitioner surgery visits per patient. There are several ways in which the management of UGI disease in the UK could be improved with regard to costs and resource utilisation, some of which are presented here. This process emphasises the value of modelling techniques to investigate the consequences of different patient management scenarios.

Anti-Inflammatory Agents, Non-Steroidal↗
PubMed2001

The use of probiotics in gastrointestinal disease.

Probiotics are living microorganisms that can affect the host in a beneficial manner. Prebiotics are nondigestible food ingredients that stimulate the growth and activity of probiotic bacteria already established in the colon. Efficacy of probiotic compounds has been shown in a wide range of gastrointestinal diseases. Lactobacillus GG alone, or the combination of Bifidobacterium bifidum and Streptococcus thermophilus, is effective in the treatment of Clostridium difficile, as well as in preventing the frequency and severity of infectious acute diarrhea in children. Prevention of antibiotic-induced diarrhea with the concomitant administration of either Lactobacillus GG or Saccharomyces boulardii has been demonstrated. The most successful studies involve the use of Lactobacillus GG at a dose of 1 x 1010 viable organisms per day and the yeast boulardii at a dose of 1 g/day. A probiotic preparation (VSL#3 - 6 g/day) that uses a combination of three species of Bifidobacterium, four strains of Lactobacillus and one strain of Streptocccus has shown promise in maintaining remission in ulcerative colitis and pouchitis, as well as in preventing the postoperative recurrence of Crohn's disease. The mechanism of action of probiotics may include receptor competition, effects on mucin secretion or probiotic immunomodulation of gut-associated lymphoid tissue. Oral administration of probiotic compounds has been demonstrated to be well tolerated and safe. However, while probiotics have the potential to improve human health and to prevent and treat some diseases, major improvements are needed in labelling and quality assurance procedures for probiotic compounds. In addition, well planned and controlled clinical studies are necessary to delineate fully the potential for probiotic compounds.

Colonic Neoplasms↗